Develops therapies for central nervous system disorders, focusing on treatments for depression and other psychiatric conditions.
NRx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of innovative therapies targeting central nervous system disorders and life-threatening pulmonary conditions. Among its notable products is ZYESAMI, an investigational drug that has successfully completed a Phase IIb/III clinical study focused on treating respiratory failure associated with COVID-19. Additionally, NRx Pharmaceuticals is advancing NRX-100 and NRX-101, oral therapeutics designed specifically for managing bipolar depression in patients experiencing acute suicidal behavior or ideation, as well as sub-acute suicidal ideation and behavior.
Founded in 2015 and headquartered in Wilmington, Delaware, NRx Pharmaceuticals is committed to addressing critical medical needs through groundbreaking research and development. The company leverages its expertise in pharmacology and clinical trials to advance novel treatment options that have the potential to significantly improve patient outcomes. NRx Pharmaceuticals collaborates closely with healthcare professionals and regulatory authorities to ensure the safe and effective progression of its therapeutic candidates.
With a focus on innovation and patient care, NRx Pharmaceuticals continues to expand its pipeline and explore new avenues for therapeutic intervention. By prioritizing rigorous scientific inquiry and patient-centric approaches, the company aims to bring transformative treatments to market, fulfilling its mission to enhance the quality of life for individuals affected by challenging medical conditions.